This page tracks new and upcoming treatment options for Parkinson’s disease (PD). What’s in development? What’s promising? What’s available soon? Current topics include BIIB094, BIIB054, NLY01, DNL151, YTX-7739, MCC950, GDNF, gene therapy, LRRK2, and more. Jump to section: News, Research, Clinical Trials
Last updated: 3 years ago
Subscribe
News
- Stem cells can repair Parkinson’s-damaged circuits in mouse brains Sep 25, 2020
- Parkinson’s disease is not one, but two diseases Sep 22, 2020
- Leading-edge technology unmasks protein linked to Parkinson’s disease Aug 19, 2020
- Epigenomic Master Regulator Enzyme Protects Against Parkinson’s Disease Aug 18, 2020
- T-006 is a potent neuroprotective and neuroregenerative agent that may have therapeutic potential in the treatment of Parkinson’s, study finds Jul 24, 2020
- The Stanford Parkinson’s Disease Plasma Study – The Science of Parkinson’s Jul 8, 2020
- Pilot study suggests Parkinson’s disease progression can be slowed Jun 30, 2020
- Solving a Parkinson’s disease puzzle through protein design: breakthrough will open up a new dimension in drug discovery for Parkinson’s disease Jun 11, 2020
- Scientists Turned Parkinson’s Disease Patient’s Skin Cells Into Brain Cells Now He Can Tie His Shoes Again May 14, 2020
- A secret experiment revealed: In a medical first, doctors treat Parkinson’s with a novel brain cell transplant May 12, 2020
- UGA researchers report possible breakthrough in Parkinson’s treatment Mar 17, 2020
- Molecule BT13 offers hope for halting Parkinson’s: has potential to boost dopamine levels and protect dopamine-producing brain cells from dying Feb 14, 2020
- San Diego biotech uses advanced stem cell techniques in hopes of rolling back the clock on Parkinson’s symptoms Dec 13, 2019
- New Molecular Drivers of Parkinson Disease Discovered, Indicating Potential Treatment Innovations Nov 20, 2019
- Fecal transplantation to treat patients with Parkinson’s disease: Hope or hype? Nov 15, 2019
- Parkinson Disease Shown to Induce Immune Imbalance in the Blood, Indicating Possible Benefit of Immune Modulation Nov 4, 2019
- Parkinson’s inhibitor enzyme presents natural therapeutic opportunity Nov 1, 2019
- Northwestern Medicine scientists have used patient-derived neurons to develop and test a new strategy to treat Parkinson’s disease Oct 16, 2019
- Yumanity Therapeutics Initiates Phase 1 Clinical Trial of Lead Candidate YTX-7739 for the Treatment of Parkinson’s Disease Oct 7, 2019
- Scientists find potential diagnostic tool, treatment for Parkinson’s disease Sep 26, 2019
- Phase 2 Trial of Gene Therapy, VY-AADC02, for Advanced Parkinson’s Enrolling in US Sep 24, 2019
- In Mice and Men, Prostate Drug Reportedly Treats Parkinson’s Disease Sep 20, 2019
- Prostate drug (terazosin) may slow Parkinson’s disease Sep 17, 2019
- Scientists listed ways of applying genetic engineering (CRISPR) to treat Parkinson’s disease Sep 10, 2019
- Engineered Protein Binds to Alpha-synuclein to Prevent Toxic Clumping, Study Reports Sep 9, 2019
- Biogen begins recruiting patients for phase 1 clinical trial of BIIB094 for Parkinson’s disease Sep 4, 2019
- Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL151 for Parkinson’s Disease Sep 3, 2019
- Nourianz Approved in US as Add-on Therapy to Carbidopa/Levodopa to Treat Off Periods in Parkinson’s Aug 29, 2019
- FDA approves new add-on drug to treat off episodes in adults with Parkinson’s disease Aug 27, 2019
- Deep brain stimulation eases Parkinson’s disease symptoms by boosting dopamine Aug 21, 2019
- Could estrogen help treat Parkinson’s? Aug 13, 2019
- Discovery could lead to new treatments for Parkinson’s, other brain diseases: Study reveals crucial role of alpha-synuclein protein in DNA repair Jul 29, 2019
- Two brain chemicals should be targeted in Parkinson’s treatment, study says Jul 17, 2019
- Nobiletin, a citrus flavonoid, has the potential to become a novel drug for the treatment of Parkinson’s, according to researchers in Japan Jul 13, 2019
- Neurocrine Biosciences Announces FDA Acceptance of New Drug Application for Opicapone as an Adjunctive Treatment for Patients with Parkinson’s Disease Jul 10, 2019
- Prevail Therapeutics Receives U.S. FDA Fast Track Designation for PR001 for the Treatment of Parkinson’s Disease Patients with a GBA1 Mutation, Plans to Initiate Phase 1/2 Clinical Trial in the Second Half of 2019 Jul 8, 2019
- Could this newly discovered protein help treat Parkinson’s? Jul 3, 2019
- Dundee partners with Bukwang Pharm to develop new treatment for Parkinson’s Jul 2, 2019
- Emerald Health Pharmaceuticals Demonstrates Neuroprotective Activity of Novel Cannabigerol Derivatives in Huntington’s and Parkinson’s Disease Models Jul 2, 2019
- Charity invests £1 million to develop a treatment to slow down progression of Parkinson’s Jul 1, 2019
- Parkinson’s, Alzheimer’s, and the New Science of Hope Jun 29, 2019
- A trial has begun in the US for the ENT-01 therapy treatment of Parkinson’s, with the first patient enrolled Jun 28, 2019
- Seelos Therapeutics Announces Acquisition of an Exclusive Worldwide License of Gene Therapy Program to Address Parkinson’s Disease from Duke University Jun 27, 2019
- Scientists track Parkinson’s journey from gut to brain in mice Jun 26, 2019
- Four New Funded Studies Use Data to Identify Parkinson’s Prevention or Treatment Options Jun 18, 2019
- Gut microbes interfere with Parkinson’s drug – but we could stop them Jun 13, 2019
- Scientists identify potential target for Parkinson’s treatment Jun 12, 2019
- Neurocrine Biosciences to Present Data on Opicapone at the 2019 World Congress on Parkinson’s Disease and Related Disorders Jun 11, 2019
- Australian trial gives new hope for Parkinson’s disease treatment Jun 11, 2019
- Parkinson’s: New gene therapy shows promise for prevention Jun 7, 2019
- Stopping Parkinson’s disease before it starts Jun 7, 2019
- Biogen Initiates Phase 1 Study of BIIB094 in Patients with Parkinson’s Disease Jun 6, 2019
- Ultrasound method restores dopaminergic pathway in brain at Parkinson’s early stages Jun 6, 2019
- Promising molecule [anle138b] targets protein to offer hope for people with Parkinson’s Jun 5, 2019
- UCB Initiates Phase 1b US-Based Multicenter Clinical Trial in Parkinson’s Disease Patients with UCB0599, a Compound Arising from the Neuropore-UCB Collaboration May 28, 2019
- Duke symposium brings together global experts to understand and develop treatments for Parkinson’s disease May 23, 2019
- Stopping inflammation in its tracks: A leap forward for new anti-inflammatory drugs [MCC950] May 13, 2019
- Neurocrine Biosciences Presents Phase III Data Analysis Demonstrating that Opicapone Added to Levodopa Resulted in a Significant and Sustained Increase in ON Time without Troublesome Dyskinesia in Parkinson’s Disease Patients May 5, 2019
- Parkinson’s disease spinal stimulation treatment restores movement – study Apr 23, 2019
- Parkinson’s implant ‘boosts the ability to walk’ as cutting edge treatment restores movement to patients who were previously left housebound Apr 22, 2019
- Parkinson’s results beyond researchers’ wildest dreams Apr 22, 2019
- Small Trial Provides New Hope Against Parkinson’s Disease Mar 1, 2019
- New Treatment Offers Potentially Promising Results for the Possibility of Slowing, Stopping, or Even Reversing Parkinson’s Disease Feb 27, 2019
- Gut Bacteria Influence the Efficacy of a Parkinson’s Drug Jan 19, 2019
Research
- Asparagine endopeptidase inhibitor protects against fenpropathrin-induced neurodegeneration via suppressing α-synuclein aggregation and neuroinflammation Sep 21, 2020
- Structure of LRRK2 in Parkinson’s disease and model for microtubule interaction Aug 19, 2020
- Gene Therapy in the Management of Parkinson’s Disease: Potential of GDNF as a Promising Therapeutic Strategy Aug 17, 2020
- Recent developments in the treatment of Parkinson’s Disease Jul 31, 2020
- Neuroprotective and neurogenic effects of novel tetramethylpyrazine derivative T-006 in Parkinson’s disease models through activating the MEF2-PGC1α and BDNF/CREB pathways Jul 24, 2020
- Identifying and predicting Parkinson’s disease subtypes through trajectory clustering via bipartite networks Jun 17, 2020
- Discovery and optimization of 3-thiophenylcoumarins as novel agents against Parkinson’s disease Jun 2, 2020
- Targeting Ubiquitin-Proteasome Pathway by Natural Products: Novel Therapeutic Strategy for Treatment of Neurodegenerative Diseases such as Parkinson’s disease Apr 28, 2020
- Glucocerebrosidase as a Therapeutic Target for Parkinson’s Disease Feb 27, 2020
- NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy Jan 3, 2020
- Neuroprotective effects of Bacopa monnieri in Parkinson’s disease model Dec 13, 2019
- Blocking CXCL12/CXCR4 may be a potential therapeutic approach for Parkinson’s disease progression Dec 12, 2019
- Targeting the microglial NLRP3 inflammasome and its role in Parkinson’s disease Nov 4, 2019
- Systemic activation of Nrf2 pathway in Parkinson’s disease Nov 4, 2019
- Editorial: Peripheral Immunity in Parkinson’s Disease: Emerging Role and Novel Target for Therapeutics Oct 15, 2019
- Targeting BDNF signaling by natural products: novel synaptic repair therapeutics for neurodegeneration and behavior disorders Sep 20, 2019
- Mitochondrial CHCHD2 and CHCHD10: Roles in Neurological Diseases and Therapeutic Implications Sep 16, 2019
- Protective and Regenerative Roles of T Cells in Central Nervous System Disorders Sep 12, 2019
- Essential role of phosphodiesterase 7 (PDE7) enzyme in neurodegeneration and inflammatory-mediated brain damage opens door to new therapeutic interventions for Parkinson’s disease Aug 31, 2019
- Hepcidin and its therapeutic potential in neurodegenerative disorders Aug 30, 2019
- Current Progress of Mitochondrial Quality Control Pathways Underlying the Pathogenesis of Parkinson’s Disease Aug 14, 2019
- The gut microbiota: A novel therapeutic target in Parkinson’s disease? Aug 12, 2019
- P1 Receptor Agonists/Antagonists – Potential Parkinson’s Drug Candidates of the Future Jul 16, 2019
- Antioxidant, Anti-inflammatory, and Neuroprotective Effects of Novel Vinyl Sulfonate Compounds as Nrf2 Activator Jul 11, 2019
- Cysteamine as a novel disease-modifying compound for Parkinson’s disease: Over a decade of research supporting a clinical trial Jul 10, 2019
- Potential Benefits of Nobiletin, A Citrus Flavonoid, against Parkinson’s Disease Jul 10, 2019
- Brain-targeted intranasal delivery of dopamine with borneol and lactoferrin co-modified nanoparticles for treating Parkinson’s disease Jul 10, 2019
- The role of high-intensity focused ultrasound as a symptomatic treatment for Parkinson’s disease Jul 10, 2019
- Recently identified therapeutic targets in dystonia based on recent preclinical animal studies and clinical trials investigating novel therapeutics Jul 4, 2019
- Protein glycation: An emerging new medicinal target area for Parkinson’s disease Jul 3, 2019
- Modulation of TMEM175 may impact α-synuclein biology and therefore may be a rational therapeutic strategy for PD Jul 2, 2019
- Mitochondrial clearance and maturation of autophagosomes are compromised in LRRK2 G2019S familial Parkinson’s disease patient fibroblasts Jul 1, 2019
- Recent advances of induced pluripotent stem cells application in neurodegenerative diseases Jun 27, 2019
- Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson’s Disease Jun 26, 2019
- α-Synuclein in Parkinson’s disease: causal or bystander? Jun 25, 2019
- Phloretin attenuates behavior deficits and neuroinflammatory response in MPTP induced Parkinson’s disease in mice Jun 25, 2019
- Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism Jun 14, 2019
- Gut microbes metabolize Parkinson’s disease drug Jun 14, 2019
- Amelioration of the nigrostriatal pathway facilitated by ultrasound-mediated neurotrophic delivery in early Parkinson’s disease Jun 10, 2019
- Current Drugs and Potential Future Neuroprotective Compounds for Parkinson’s Disease Jun 4, 2019
- Defining α-synuclein species responsible for Parkinson disease phenotypes in mice May 29, 2019
- Focused ultrasound opening of the blood-brain barrier for treatment of Parkinson’s disease May 28, 2019
- Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting α-synuclein as a novel therapy for Parkinson’s disease May 21, 2019
- Lysosomal exocytosis is a potential therapeutic target in Parkinson’s and other diseases characterized by the accumulation of a-synuclein May 16, 2019
- Targeting kinases in Parkinson’s disease: A mechanism shared by LRRK2, neurotrophins, exenatide, urate, nilotinib and lithium May 15, 2019
- MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition [abstract-only] May 13, 2019
- PDZ Scaffold Protein CAL Couples with Metabotropic Glutamate Receptor 5 to Protect Against Cell Apoptosis and Is a Potential Target in the Treatment of Parkinson’s Disease May 9, 2019
- FTY720 may reduce Parkinson’s disease progression by inhibiting NLRP3 inflammasome activation May 8, 2019
- Evaluating ADS5102 (amantadine) for the treatment of Parkinson’s disease patients with dyskinesia May 6, 2019
- Marine-Derived Natural Compounds for the Treatment of Parkinson’s Disease Apr 11, 2019
- Neuroprotective Effects of Thymol, a Dietary Monoterpene Against Dopaminergic Neurodegeneration in Rotenone-Induced Rat Model of Parkinson’s Disease Mar 27, 2019
- Histamine N-Methyltransferase in the Brain Feb 10, 2019
- The Potential of L-Type Calcium Channels as a Drug Target for Neuroprotective Therapy in Parkinson’s Disease Jan 6, 2019
Clinical Trials
- A Clinical Study of NLY01 in Patient’s With Early Parkinson’s Disease Aug 18, 2020
- Microbiota Intervention to Change the Response of Parkinson’s Disease Aug 14, 2020
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson’s Disease Aug 5, 2020
- Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson’s Disease Jul 9, 2020
- Simvastatin as a Neuroprotective Treatment for Moderate Parkinson’s Disease Jun 1, 2020
- TSPO-PET for Neuroinflammation in Parkinson’s Disease Apr 27, 2020
- A Phase 3 Study With P2B001 in Subjects With Early Parkinson’s Mar 10, 2020
- Effect of Melatonin Administration on the PER1 and BMAL1 Clock Genes in Patients With Parkinson’s Disease Feb 27, 2020
- Brain Bioenergetics in Parkinson’s Disease and Response to Repeated Oral UDCA Treatment Nov 1, 2019
- A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment Associated With Parkinson’s Disease Nov 1, 2019
- Transplantation of Neural Stem Cell-Derived Neurons for Parkinson’s Disease Sep 26, 2019
- Study to Evaluate APL-130277 in Subjects With Parkinson’s Disease Complicated by Motor Fluctuations Sep 25, 2019
- Extension Study of Ampreloxetine (TD-9855) for Treating snOH in Subjects With Primary Autonomic Failure Sep 19, 2019
- Study to Evaluate DNL151 in Subjects With Parkinson’s Disease Sep 18, 2019
- A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson’s Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER-214 Sep 18, 2019
- Open-label Investigation of the Safety and Clinical Effects of NTCELL in Patients With Parkinson’s Disease Sep 16, 2019
- Study to Investigate the Effect of IPT803 Adjunct Treatment in Patients With Parkinson’s Disease Sep 4, 2019
- Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral, Idiopathic Parkinson’s Disease Aug 30, 2019
- Study of UB-312 in Healthy Participants and Parkinson’s Disease Patients Aug 30, 2019
- SRC Inhibition as a Potential Target for Parkinson’s Disease Psychosis Aug 13, 2019
- A Clinical Trial Investigating the Efficacy, Safety and Tolerability of ND0612 Infusion in Subjects With Parkinson’s Disease Experiencing Motor Fluctuations Jul 3, 2019
- Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson’s Disease Jul 3, 2019
- Dose Escalation Study of Cu(II)ATSM in Parkinson’s Disease Jun 25, 2019
- Trial of Ursodeoxycholic Acid (UDCA) for Parkinson’s Disease: The “UP” Study Jun 11, 2019
- Chronic Effects of DBS in Parkinson’s Disease and Dystonia Jun 5, 2019
- Study to Evaluate DNL201 in Subjects With Parkinson’s Disease Jun 5, 2019
- BTRX-246040 Study in Subjects With Parkinson’s Disease With Motor Fluctuations [Completed] Jun 5, 2019
- Clinical Trial to Evaluate the Safety and Tolerability of Molecular Hydrogen in Patients With Parkinson’s Disease Jun 3, 2019
- Effects of Lingzhi (Ganoderma) on Disease Progression in Patients With Untreated Early Parkinson’s Disease May 29, 2019
- Modulation of Gut Microbiota by Rifaximin in PD Patients May 22, 2019
- A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson’s Disease and Cognitive Impairment May 22, 2019
- A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson’s Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation May 22, 2019
- Safety and Efficacy of THN102 in Patients With Parkinson’s Disease and Excessive Daytime Sleepiness May 21, 2019
- VY-AADC02 for Parkinson’s Disease With Motor Fluctuations May 20, 2019
- A Phase 1 Study to Assess the Safety, Tolerability and PK of NPT520-34 in Healthy Subjects May 17, 2019
- A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson’s Disease Patients With Motor Fluctuations May 16, 2019
- A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson’s Disease May 15, 2019
- Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5HT2A Inverse Agonist, to Treat Impulse Control Disorders in Parkinson’s Disease May 13, 2019
- Single Ascending Dose Study of MEDI1341 in Healthy Volunteers May 13, 2019
